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Purpose: Sac regression is a surrogate marker for clinical success in endovascular aneurysm repair (EVAR) and has been
shown to be device-specific. The low porosity Excluder endograft (Excluder low-permeability endoprosthesis [ELPE];
W. L. Gore & Associates Inc, Flagstaff, Ariz) introduced in 2004 was reported in early follow-up to be associated with
sac regression rates similar to other endografts, unlike the original Excluder which suffered from sac growth secondary
to fluid accumulation in the sac. The purpose of this study was to determine whether this behavior is durable in mid-term
to long-term follow-up.
Methods:Between July 2004 andDecember 2007, 301 patients underwent EVAR of an abdominal aortic aneurysm (AAA)
with the ELPE at two institutions. Baseline sac size was measured by computed tomography (CT) scan at 1 month after
repair. Follow-up beyond 1 year was either with a CT or ultrasound scan. Changes in sac size>5 mm from baseline were
determined to be significant. Endoleak history was assessed with respect to sac behavior using 2 and logistic regression
analysis.
Results: Two hundred sixteen patients (mean age 73.6 years and 76%men) had at least 1-year follow-up imaging available
for analysis. Mean follow-up was 2.6 years (range, 1-5 years). The average minor-axis diameter was 52 mm at baseline.
The proportion of patients with sac regression was similar during the study period: 58%, 66%, 60%, 59%, and 63% at 1 to
5 years, respectively. The proportion of patients with sac growth increased over time to 14.8% at 4-year follow-up. The
probability of freedom from sac growth at 4 years was 82.4%. Eighty patients (37.7%) had an endoleak detected at some
time during follow-up with 29.6% (16 of 54) residual endoleak rate at 4 years; 13 of the residual 16 endoleaks were type
II. All patients with sac growth had endoleaks at some time during the study compared with only 18% of patients with
sac regression (P < .0001).
Conclusion: A sustained sac regression after AAA exclusion with ELPE is noted up to 5-year follow-up. Sac enlargement
was observed only in the setting of a current or previous endoleak, with no cases of suspected hygroma formation noted.
(J Vasc Surg 2011;53:1178-83.)
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tAbdominal aortic aneurysms (AAAs) are routinely
treated with endovascular repair (endovascular aneurysm
repair [EVAR]) safely and with good short-term results.1,2
Early data have shown that sac behavior after EVAR is
device-specific.3,4 Reports from the Regulatory Trial using
the Original Gore Excluder (OGE; W. L. Gore & Associ-
ates Inc, Flagstaff, Ariz) showed that 14% of patients expe-
rienced sac growth at 2 years after an EVAR.5 Subse-
quently, we reported an alarming sac growth in 37% of
patients at 4-year follow-up due to either continuous sac
growth or re-expansion of once shrunken aneurysm sacs.6
Sac growth in several patients occurred in the absence of
endoleaks and was attributed to transgraft flow of serous
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1178uid, hygroma formation, and endotension. These findings
ed to the modification of the OGE with the addition of a
ew low-permeability layer. The new Excluder low-
ermeability endoprosthesis (ELPE) was released in mid-
004. It incorporates a low-porosity film into the construct
f the device making it impermeable to fluids while main-
aining the same luminal and abluminal surfaces, device
aterial thickness, deliverability, and device handling char-
cteristics. Early assessments suggested these modifications
nhanced sac regression similar to other endografts.7,8
owever, it has not been established yet whether sac re-
ression is sustainable past 1 year and whether hygroma
ormation is no longer a threat in the long term. In this
tudy, we sought to evaluate the mid-term to long-term sac
ehavior after EVAR with the ELPE.
ETHODS
From July 2004 throughDecember 2007, 301 patients
nderwent elective EVAR at two institutions using the
LPE device. There were 216 patients with at least 1-year
ollow-up imaging data available for sac behavior and en-
oleak analysis. The institutional review boards at the
orthwestern University Feinberg School of Medicine and
he University of Pittsburgh School of Medicine approved
he study protocol. Follow-up schedules were slightly dif-
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Volume 53, Number 5 Hogg et al 1179ferent between institutions and evolved over time. Patients
were universally scheduled to undergo an abdominal com-
puted tomography (CT) scan at 1 and 12 months after
implantation with yearly follow-up thereafter. At one insti-
tution, Duplex ultrasonography scan replaced CT scanning
in some patients with impaired renal function or shrinking
aneurysm sacs after the first year of follow-up, and in
patients with stable sacs after 2 years.9 The other institution
continued to utilize CT imaging in all patients. In the renal
impaired, sac size was determined from noncontrast CT
images and endoleaks were sought using Duplex ultra-
sound scan. The presence or absence of an endoleak was
determined either by Duplex scan or by CT scans per-
formed with early and late phase–contrast-enhanced imag-
ing.
The method used for measuring changes in dimension
of the aneurysm was in accordance with the Society for
Vascular Surgery reporting standards for EVAR.10 Both
major and minor axes were measured from adventitia to
adventitia on a digital workstation for CT scans. Similar
measurements were obtained on transverse duplex scans
perpendicular to the centerline of the aneurysm. AAA sac
size change was determined by comparing the minor axis
measurements between the baseline and all subsequent
imaging; major axis measurements were not used as they do
not necessarily represent the true diameter of the AAA, as
the AAA sac may not be parallel to the axis of the body. Sac
size at 1 month was used as baseline measurement as
pretreatment size may not accurately represent preopera-
tive size, as there may be a significant variability in time
interval between the last preoperative imaging and repair.
Sac diameter size change of 5 mm was considered signif-
icant. All CT measurements were done by the treating
physicians. Statistical analysis was performed using statisti-
cal software R (version 2.11.0). Quantitative values were
calculated using regression analysis while categorical values
were analyzed using the 2 test or the Fisher exact test.
Values are listed as mean  SD. Kaplan-Meier curves were
used to assess freedom from sac growth over time.
RESULTS
Clinical results. Device implantation was successful in
all but 1 patient due to failure to access the contralateral
limb. This patient subsequently underwent aneurysm repair
with an aorto-uni-iliac device (Renu; Cook Medical Inc,
Bloomington, Ind). Perioperative deaths occurred in 6
patients after placement of an ELPE: 1 patient from colonic
ischemia, 2 patients from pneumonia, and 3 patients within
30 days from other comorbidities yielding a total mortality
of 1.99%. A perioperative stroke occurred in 1 patient, but
no patient suffered a perioperative myocardial infarction.
One patient with chronic renal insufficiency went on to
develop endstage renal disease from contrast-induced ne-
phropathy requiring temporary dialysis.
Total perioperative and late graft-related complications
are detailed in the Table. Two patients had early limb
complications, one associated with thrombosis of the com-
mon femoral artery requiring open repair, and the other uas repaired with an iliac stent. Four additional patients had
ate limb complications requiring subsequent stent place-
ent.
Sac size change. Baseline AAA sac size was 51.8 8.3
m. There were 71 patients whose AAA measured 5 cm
t baseline, of whom 16 patients had AAAs that measured
5 cm on preoperative imaging studies. For the remaining
5 patients, the indications for repair were as follows:
accular aneurysm, 6 patients; large iliac aneurysm, 7 pa-
ients; rapid growth rate, 10 patients; desire for reasons
uch as strong family history/anxiety, 13 patients; sur-
eons’ discretion for steadily growing AAAs that were
lmost but not quite 5 cm, 12 patients; symptomatic but
ot emergent AAA, 7 patients. Follow-up imaging was
one by CT scans in the majority of patients (77%). The
ean follow-up was 2.6  1.3 years (range, 1-5 years).
Fig 1 illustrates the distribution of patients with differ-
nt sac behaviors during follow-up. The proportion of
atients with sac regression did not differ statistically over
he course of follow-up: 58%, 66%, 60%, 59%, and 63% at 1
o 5 years, respectively (P .65). Similarly, the proportion
f patients with no change in sac size was equivalent during
ollow-up: 40%, 29%, 30%, 26%, and 33%, respectively (P
84). However, a steady increase was noted over time in the
ercentage of patients with sac growth reaching nearly 15%
n the 4-year imaging studies.
Sac regression was observed in 134 patients at last
ollow-up. The mean decrease in sac diameter was 14.1 
.7 mm among patients with sac regression. Thirty-nine
atients had a decrease between 5 to 9 mm, 66 patients
etween 10 to 19 mm, 28 patients between 20 to 29 mm,
nd 1 patient over 30 mm.
During the course of follow-up, 17 patients manifested
n increase in sac size by 5 mm compared with baseline.
he mean increase in sac size was 13.2 7.7 mm. Increase
n size between 5 to 9 mmwas noted in 8 patients, between
0 to 19 mm in 7 patients, between 20 to 29 mm in 1
atient and 30 mm in 1 patient. Two patients ultimately
equired elective open conversion and device explantation.
n 1 patient, the AAA sac expanded by 34 mm despite
ultiple interventions to treat endoleaks (attempted coil
mbolization, proximal and distal extensions, and banding
f a common iliac artery via a retroperitoneal exposure) and
able. Early and late complications after EVAR with the
xcluder low-porosity endoprosthesis
eported complications No. of patients %
erioperative death 6 1.9
ailure to deploy device 1 0.3
troke 1 0.3
enal failure 1 0.3
raft infection 1 0.3
imb dissection/thrombosis 2 0.7
igration 4 1.3
upture (late) 2 0.7
VAR, Endovascular aneurysm repair.ltimately underwent open conversion at 3.5 years after
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May 20111180 Hogg et alEVAR. The other patient who underwent initial EVAR
with a very short neck of approximately 8 mm was lost to
follow-up after 1 month. He presented with a right limb
occlusion and distal migration of the endograft into the sac
3 years later. He underwent an uneventful open surgical
reconstruction.
Re-expansion beyond baseline after initial shrinkage of
the AAA sac occurred in 2 of these 17 patients. They both
had a decrease in sac size by 5 mm initially but the sac
re-expanded by 6 mm above baseline at 3 years in 1 patient
and by 5 mm at 4 years in the other despite an earlier coil
embolization of a lumbar artery; they both had type II
endoleaks.
The probability of freedom from sac growth compared
to baseline measurements for the entire cohort of patients
was 98.3% at 2 years, 92.8% at 3 years, 82.4% at 4 years, and
78.9% at 5 years based on Kaplan-Meier estimates (Fig 2).
Endoleak. Of the 216 patients, 212 (98%) had en-
doleak data available for analysis. Eighty patients (37.7%)
had evidence of endoleak at some point during follow-up,
while at 4-year imaging, 16 of 54 patients still demon-
strated an endoleak (29.6%); 3 were type I and 13 type II.
At last follow-up, 56 patients (26.5%) had endoleaks: 8
patients had type Is and 48 type IIs. No type III endoleaks
were noted. It is of interest to note that of the 8 patients
with type I endoleak, 4 patients had no sac change, 2
patients had sac regression, and 2 patients had sac growth.
Both patients with sac growth required open conversion
with device explantation as detailed above.
All 17 patients with sac growth had endoleaks at some
Fig 1. Percentage of patients with stable, shrinking, o
follow-up interval compared with baseline measurementtime during follow-up. In comparison, only 18% patients w24 of 134) who exhibited sac regression had an endoleak
t any time (P  .0001). All but 1 of 17 patients with sac
xpansion continued to have evidence of an endoleak at last
ollow-up. Patients without significant sac size change had
n even split between the presence and absence of en-
oleaks. The probability of freedom from sac growth at 4
ears was 100% for patients without and 61.2% for those
arging abdominal aortic aneurysm (AAA) sac at each
ig 2. Probability of freedom from abdominal aortic aneurysm
AAA) sac enlargement compared with baseline after endovascular
epair of AAA with low permeability Excluder endoprosthesis.r enlith history of endoleaks (Fig 3).
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Volume 53, Number 5 Hogg et al 1181An endoleak was detected at last follow-up in 46 of 151
patients (30%) of CT scans compared with 10 of 65 patients
(15%) of Duplex scans. This may be related to the fact that
follow-up imaging modality was switched to Duplex scans
in patients with stable or shrinking AAA sacs.
Late ruptures. There were two late fatal ruptures in
the present series. One initially underwent EVAR with an
unfavorable proximal neck anatomy due to prohibitive
cardiac condition for an open repair. He was noted to have
a type I endoleak with slow sac enlargement by 11 mm at
4.5 years for which coil embolization was attempted. By
5-year follow-up, the AAA sac had grown 14 mm larger
than baseline; he underwent proximal extension with the
use of a “chimney” graft to preserve one of the two renal
arteries at 5.5 years. He presented 2 months later with a
rupture and died on the operating table. The other rupture
occurred in a patient who had a stable AAA sac with no
endoleaks during her first 2 years of follow-up. Unfortu-
nately, she had just missed her 3-year follow-up appoint-
ment when her AAA ruptured. She was noted to have a type
II endoleak from lumbar arteries and underwent surgical
graft implantation, but died in the hospital.
DISCUSSION
Several studies have reported on a short-term sac be-
havior after EVAR using the Excluder device.7,8,11 We
previously reported that sac regression rate 1 year after
EVAR with ELPE was significantly higher compared with
the OGE (63.9% vs 25%, respectively) and that it was
similar to that of the Zenith (Cook Medical Inc, Bloom-
ington, Ind) endograft (65.3%).8 Tanski et al7 observed a
significantly decreased sac size and 3-dimensional volume
Fig 3. Probability of freedom from abdominal aortic aneurysm
(AAA) sac enlargement in patients with and without current or
previous endoleaks compared with baseline after endovascular
repair of AAA with low permeability Excluder endoprosthesis. EL,
Endoleak.with ELPE (5.1 mm and 20%, respectively) compared iith OGE (2.1 mm and 6%, respectively). Broker et
l,11 on the contrary, noted a significantly lower absolute
ac regression with the ELPE device (34%) as compared
ith the Zenith (63%) and AneuRx (Medtronic Vascular,
anta Rosa, Calif) endografts (65%) at 18-months follow-
p. Later follow-up on the ELPE device, however, has not
et been reported until now.
The present study illustrates a significant rate of AAA
ac regression that is sustained during the first 5 years of
ollow-up. The 59% 4-year sac regression rate with ELPE
een in this study compares favorably to a 4-year 21% sac
egression rate we reported with the original Excluder6 and
t remains comparable to the 1-year sac shrinkage rate we
eported with ELPE.8
While a rare event, this study again shows that a once
hrunken sac may re-expand.6 This was observed in 2
atients, at 3-year and 4-year follow-up, and highlights the
eed for continued surveillance even in the setting of sac
egression.
As with all EVAR procedures and all endograft devices,
he presence of endoleaks may ultimately lead to enlarge-
ent of the sac. The sac growth rate in this study was 15%
t 4 years after EVAR. Although not as high as was seen
ith the OGE (37% at 4 years), it remains significant. It
hould be noted, however, that no significant sac enlarge-
ent to date has been observed in the absence of a previous
r current endoleak. No patients were suspected of having
sac expansion due to hygroma in the absence of an
ndoleak. It thus appears that the modification of the
xcluder device with the addition of the low porosity layer
ay have been successful in eliminating transgraft flow that
ccounted for 74% of sac growths in the OGE trial.12 The
ncidence of history of endoleak in the present study was
4%, within the range currently reported in the litera-
ure.8,13-17 As with all endografts, however, incomplete
xclusion may lead to a continued expansion of the sac,
hich has to be monitored carefully through continued
maging. It is possible that the increasing number of pa-
ients with growing sacs over the course of follow-up may
e related to increasing incidence of endoleak development
s follow-up duration increases or delayed onset of trans-
raft flow of serous fluid. The decrease in sac growth rate
bserved at 5 years may reflect a type II statistical error
elated to the small number of observations at that time
eriod.
The natural history of AAA sac change after EVAR in
he presence of a type II endoleak remains to be defined.
iscrepancies exist in the literature regarding adverse se-
uelas as a result of blood flow within the aneurysm sac.
ust as sac behavior has been determined to be device-
pecific, the percentage of postoperative endoleaks after
VAR has been reported to vary from 18% to 65%.14-17
uriel et al3 showed that type II endoleaks are graft-
ependent with the highest rate of endoleak observed with
he OGE (58%) compared to the Talent device (Medtronic
ascular) which had the lowest rate (19%). Sheehan et al,18
owever, in a later study showed that this initial variability
n the incidence of endoleaks were obliterated over time
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May 20111182 Hogg et alwith similar rates of spontaneous endoleak resolution and
late endoleak development. The proportion of patients
with endoleaks at last follow-up was 25% in the current
study, in accordance with the findings of other studies7,11
that showed a higher incidence of endoleak in patients with
sac growth than in those with sac regression.
Data on the effects of endoleak on sac growth and their
potential graft-specific nature are conflicting. Fairman et
al14 in a multicenter study of 351 patients treated with the
Zenith endograft noted that endoleaks were predictive of
sac growth. Greenberg et al,13 observed that, in the pres-
ence of a small endoleak, the aneurysms treated with a
Zenith endograft would decrease in volume, whereas those
treated with the OGE would expand. Jones et al,15 in a
series of 873 patients undergoing EVAR with 10 different
stent grafts at a single institution, reported that endoleaks
were associated with sac growth and rupture. Statistical
analysis breaking the cohort into subgroups based on stent
graft was not performed to determine whether these find-
ings were procedure-specific or device-specific.15 The Eu-
ropean Collaborators on Stent/graft Techniques for aortic
Aneurysm Repair (EUROSTAR) experience, with 2463
patients from 87 European centers, had enough patients to
perform a power analysis based on endoleak type combin-
ing patients with type I and III endoleaks.16 They found
that type I and III, but not type II, endoleaks correlated
with increased risk of rupture, but changes in aneurysm sac
size was not included in this analysis. The absence of
endoleak, however, does not always imply an uncompli-
cated course. Zarins et al19 reported 7 ruptures in 1046
patients who underwent EVAR using the AneuRx device; 5
had no evidence of endoleak. In a series from theUniversity
of Pittsburgh of ruptured AAA with antecedent EVAR,
most patients had no evidence of endoleak at last follow-up
imaging before the rupture.20
There are several limitations in this study. It is a retro-
spective analysis of one device without another device for
comparison. A significant number of patients were either
lost to follow-up or had no imaging for review and may
have introduced a selection bias. Being tertiary referral
centers, a significant portion of our patients are referred
from great distances. Unfortunately, these patients do not
want to travel such great distances for follow-up. This
makes it difficult for complete follow-up of these patients,
explaining a relatively high attrition rate in follow-up. A
selection bias may also have been introduced by following
more closely patients with endoleaks, increasing their rep-
resentation in the sample. In addition, patients with sac
growth may be more apt to get serial imaging than those
who have had partial or complete sac regression. Finally,
not all patients underwent CT evaluation with contrast
enhancement as the only imaging modality. Patients with
compromised renal function or contrast allergy or those
with stable or shrinking sacs were switched to Duplex scans
at one institution introducing a possible error in size com-
parisons. The accuracy of Duplex relative to CT imaging,
however, is well validated and has been shown in recent
studies.9,21
1ONCLUSIONS
The ELPE has shown a sustained sac regression rate up
o 5-year follow-up. The addition of a low porosity layer in
he ELPE seems to have eliminated the transgraft flow of
erous fluid and hygroma formation. Although AAA sac
nlargement continues to be observed, it seems to be
estricted to patients with current or previous endoleaks.
onger-term follow-up data would be necessary to place
his finding into proper perspective. As with all EVAR
atients, continued surveillance is mandatory even in pa-
ients with stable or shrinking AAA sacs to better under-
tand late performance and help prevent late complications.
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